SCHEMBL2532843

SCHEMBL2532843

O=Cc1c[nH]c2c(F)ccc(F)c12

nearest known ligand 0.41

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 2/20 0.41
TRIM24 O15164 1/20 0.41
TRIM33 Q9UPN9 1/20 0.41
ERN1 O75460 3/20 0.38
HTR1D P28221 3/20 0.38
HTR1B P28222 2/20 0.38
IMPDH2 P12268 1/20 0.37
PIM3 Q86V86 7/20 0.37
PIM1 P11309 5/20 0.37
PIM2 Q9P1W9 2/20 0.37
HTR1A P08908 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14663023 0.85 CYP2A6 (0.51) CYP2A6TRIM24TRIM33ERN1HTR1D
SCHEMBL12152010 0.85 TRIM24 (0.51) CYP2A6TRIM24TRIM33ERN1HTR1D
SCHEMBL12152064 0.85 CYP2A6 (0.37) CYP2A6TRIM24TRIM33ERN1HTR1D
SCHEMBL3034999 0.85 CYP2A6 (0.37) CYP2A6TRIM24TRIM33ERN1HTR1D
SCHEMBL12151973 0.85 CYP2A6 (0.47) CYP2A6TRIM24TRIM33ERN1HTR1D
SCHEMBL1420426 0.81 CYP2A6 (0.34) CYP2A6TRIM24TRIM33ERN1HTR1D
SCHEMBL6362825 0.80 CASP6 (0.44) CYP2A6TRIM24TRIM33ERN1HTR1D
SCHEMBL22531704 0.80 CASP6 (0.51) CYP2A6TRIM24TRIM33ERN1
SCHEMBL2537976 0.77 HTR1D (0.41) CYP2A6TRIM24TRIM33ERN1HTR1D
SCHEMBL10266797 0.77 HDAC1 (0.38) TRIM24TRIM33ERN1PIM3PIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1859798-B1 N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR LILLY CO ELI (US) 2015-12-30 EP disclosed
US-8044090-B2 N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor ELI LILLY (US) 2011-10-25 US disclosed
US-20090306110-A1 N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR CHEN ZHAOGEN 2009-12-10 US disclosed
EP-1859798-A1 N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR ELI LILLY AND COMPANY (US) 2007-11-28 EP disclosed
EP-1379239-B1 N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR LILLY CO ELI (US) 2007-09-12 EP disclosed
US-20070099909-A1 N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR CHEN ZHAOGEN 2007-05-03 US disclosed
US-7157488-B2 N-(2-Arylethyl) benzylamines as antagonists of the 5-HT6 receptor ELI LILLY AND COMPANY (US) 2007-01-02 US disclosed
US-20060009511-A9 N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor CHEN ZHAOGEN 2006-01-12 US disclosed
EP-1379239-A2 N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR ELI LILLY AND COMPANY (US) 2004-01-14 EP disclosed
WO-2002078693-A2 N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR ELI LILLY AND COMPANY (US) 2002-10-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060009511-A9 N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor HTR6, HTR2C, HTR1B CYP2A6 202/4885TRIM24 4408/4885TRIM33 4769/4885
US-20090306110-A1 N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR HTR6, HTR2C, HTR1B CYP2A6 202/4885TRIM24 4408/4885TRIM33 4769/4885
US-20070099909-A1 N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR HTR6, HTR2C, HTR1B CYP2A6 202/4885TRIM24 4408/4885TRIM33 4769/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.